無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

若年性黄斑変性症 (シュタルガルト病) :世界の治験動向

Juvenile Macular Degeneration (Stargardt Disease) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 347925
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.41円で換算しております。
Back to Top
若年性黄斑変性症 (シュタルガルト病) :世界の治験動向 Juvenile Macular Degeneration (Stargardt Disease) Global Clinical Trials Review, H2, 2017
出版日: 2017年10月31日 ページ情報: 英文 48 Pages
概要

当レポートでは、若年性黄斑変性症 (シュタルガルト病) 治療薬の治験に関する最新動向について分析しており、主要国における治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、企業や研究機関における研究の進行状況、有望な薬剤の比較などの情報を提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:眼科疾患治療薬の治験における若年性黄斑変性症 (シュタルガルト病) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:眼科疾患治療薬の治験における若年性黄斑変性症 (シュタルガルト病) の割合

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

若年性黄斑変性症 (シュタルガルト病) 治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

目次
Product Code: GDHC4682CTIDB

GlobalData's clinical trial report, "Juvenile Macular Degeneration (Stargardt Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Juvenile Macular Degeneration (Stargardt Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Juvenile Macular Degeneration (Stargardt Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
  • Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
    • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Juvenile Macular Degeneration (Stargardt Disease)
      • Oct 26, 2017: Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
      • Sep 10, 2017: Acucela Receives New Patent Covering Method of Use for Emixustat Hydrochloride
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
  • Source

List of Tables

  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Region, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Europe, Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
  • Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, G7 Countries (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, E7 Countries (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures

  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Europe, Top Countries (%), 2017*
  • Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, G7 Countries (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Juvenile Macular Degeneration (Stargardt Disease) to Ophthalmology Clinical Trials, E7 Countries (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Juvenile Macular Degeneration (Stargardt Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • GlobalData Methodology
Back to Top